4Dmedical Financials
4DX Stock | 0.46 0.01 2.22% |
Operating Margin (7.55) | EPS Estimate Current Year (0.08) | Return On Equity (0.51) |
4Dmedical | Select Account or Indicator |
Understanding current and past 4Dmedical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of 4Dmedical's financial statements are interrelated, with each one affecting the others. For example, an increase in 4Dmedical's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in 4Dmedical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of 4Dmedical. Check 4Dmedical's Beneish M Score to see the likelihood of 4Dmedical's management manipulating its earnings.
4Dmedical Stock Summary
4Dmedical competes with Aneka Tambang, Woolworths, Commonwealth Bank, BHP Group, and Rio Tinto. 4Dmedical is entity of Australia. It is traded as Stock on AU exchange.Foreign Associate | Germany |
Specialization | Health Care, Health Care Equipment & Services |
Instrument | Australia Stock View All |
Exchange | Australian Securities Exchange |
ISIN | AU0000095416 |
Business Address | Melbourne Connect, Carlton, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | 4dmedical.com |
Phone | 61 3 9545 5940 |
You should never invest in 4Dmedical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of 4Dmedical Stock, because this is throwing your money away. Analyzing the key information contained in 4Dmedical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
4Dmedical Key Financial Ratios
4Dmedical's financial ratios allow both analysts and investors to convert raw data from 4Dmedical's financial statements into concise, actionable information that can be used to evaluate the performance of 4Dmedical over time and compare it to other companies across industries.Revenue | 3.75 M | ||||
Gross Profit | 684.43 K | ||||
EBITDA | (31.86 M) | ||||
Net Income | (35.98 M) | ||||
Total Asset | 120.02 M |
4Dmedical Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 15.8M | 92.6M | 74.3M | 92.9M | 120.0M | 126.0M | |
Other Current Liab | 9.0M | 969.8K | 6.6M | 11.6M | 18.5M | 19.4M | |
Net Debt | 8.1M | (79.2M) | (44.9M) | (64.4M) | (25.5M) | (26.8M) | |
Retained Earnings | (38.6M) | (60.0M) | (84.6M) | (116.1M) | (152.0M) | (144.4M) | |
Accounts Payable | 1.7M | 448.2K | 1.8M | 2.9M | 2.1M | 1.1M | |
Cash | 8.4M | 80.9M | 51.1M | 69.6M | 30.6M | 27.1M | |
Inventory | 16.0K | 153.4K | 1.5K | 665.0K | 992.2K | 1.0M | |
Other Current Assets | 489.0K | 4.4M | 1.4M | 7.5M | 6.2M | 6.5M | |
Total Liab | 27.6M | 9.3M | 14.8M | 21.5M | 49.1M | 51.5M | |
Total Current Assets | 10.3M | 85.8M | 58.9M | 78.5M | 39.1M | 31.3M | |
Intangible Assets | 512.9K | 3.9M | 5.1M | 5.1M | 29.5M | 30.9M | |
Common Stock | 18.9M | 141.6M | 141.7M | 184.4M | 218.4M | 229.4M | |
Other Liab | 55.3K | 146.6K | 104.6K | 185.8K | 213.7K | 224.3K | |
Net Tangible Assets | (12.3M) | 82.7M | 58.5M | 70.4M | 81.0M | 85.1M | |
Other Assets | 2.9M | 3.3M | 4.1M | 4.1M | 4.7M | 2.5M | |
Net Receivables | 1.8M | 426.6K | 6.4M | 815.0K | 1.3M | 1.7M | |
Long Term Debt Total | 621.2K | 965.4K | 5.1M | 4.2M | 4.8M | 5.1M | |
Short Term Debt | 16.2M | 723.5K | 1.1M | 933.1K | 944.6K | 897.4K |
4Dmedical Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Revenue | 1.2M | 217.0K | 1.1M | 282.2K | 3.8M | 3.9M | |
Gross Profit | (8.1M) | 125.1K | 280.6K | 248.0K | 3.5M | 3.7M | |
Operating Income | (16.0M) | (18.8M) | (36.8M) | (31.1M) | (28.0M) | (26.6M) | |
Ebit | (16.4M) | (18.8M) | (37.8M) | (36.3M) | (35.9M) | (34.1M) | |
Ebitda | (15.8M) | (18.0M) | (36.3M) | (33.7M) | (31.9M) | (30.3M) | |
Cost Of Revenue | 9.4M | 91.9K | 773.7K | 34.1K | 236.7K | 224.9K | |
Income Before Tax | (22.8M) | (21.4M) | (24.5M) | (31.1M) | (40.4M) | (38.4M) | |
Net Income | (22.0M) | (21.4M) | (24.6M) | (31.5M) | (36.0M) | (34.2M) | |
Tax Provision | 1.8K | 15.3K | 43.2K | 323.2K | 48.4K | 60.0K | |
Interest Expense | 8.0M | 2.6M | 179.6K | 6.5K | 264.0K | 250.8K | |
Income Tax Expense | (818.0K) | 15.3K | 43.2K | 323.2K | (4.4M) | (4.2M) | |
Interest Income | 8.0M | 2.7M | 92.6K | 313.6K | 1.2M | 1.4M | |
Research Development | 3.5M | 2.4M | 4.4M | 4.0M | 694.5K | 659.8K |
4Dmedical Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | 612.7K | (137.3K) | (273.1K) | (663.5K) | 327.2K | 343.6K | |
Change In Cash | 5.3M | 72.5M | (29.8M) | 18.5M | (39.0M) | (37.0M) | |
Free Cash Flow | (8.8M) | (15.2M) | (28.3M) | (23.4M) | (31.2M) | (29.6M) | |
Depreciation | 584.7K | 741.5K | 1.5M | 2.6M | 4.1M | 4.3M | |
Other Non Cash Items | 9.8M | 1.5M | 582.1K | 1.4M | 344.1K | 326.9K | |
Capital Expenditures | 1.2M | 725.0K | 3.1M | 731.3K | 302.9K | 287.7K | |
Net Income | (22.0M) | (21.4M) | (24.6M) | (31.5M) | (36.0M) | (34.2M) | |
End Period Cash Flow | 8.4M | 80.9M | 51.1M | 69.6M | 30.6M | 27.1M | |
Net Borrowings | 14.1M | (533.7K) | (995.5K) | 170.6K | 153.5K | 145.8K | |
Change To Netincome | 10.8M | 1.5M | 582.1K | 1.4M | 1.7M | 2.4M |
4Dmedical Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining 4Dmedical's current stock value. Our valuation model uses many indicators to compare 4Dmedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across 4Dmedical competition to find correlations between indicators driving 4Dmedical's intrinsic value. More Info.4Dmedical is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the 4Dmedical's earnings, one of the primary drivers of an investment's value.4Dmedical Systematic Risk
4Dmedical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. 4Dmedical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on 4Dmedical correlated with the market. If Beta is less than 0 4Dmedical generally moves in the opposite direction as compared to the market. If 4Dmedical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one 4Dmedical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of 4Dmedical is generally in the same direction as the market. If Beta > 1 4Dmedical moves generally in the same direction as, but more than the movement of the benchmark.
4Dmedical Total Assets Over Time
4Dmedical Thematic Clasifications
4Dmedical is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
Drugs | View |
4Dmedical December 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of 4Dmedical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of 4Dmedical. We use our internally-developed statistical techniques to arrive at the intrinsic value of 4Dmedical based on widely used predictive technical indicators. In general, we focus on analyzing 4Dmedical Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build 4Dmedical's daily price indicators and compare them against related drivers.
Downside Deviation | 4.76 | |||
Information Ratio | 0.0344 | |||
Maximum Drawdown | 51.76 | |||
Value At Risk | (6.25) | |||
Potential Upside | 7.94 |
Additional Tools for 4Dmedical Stock Analysis
When running 4Dmedical's price analysis, check to measure 4Dmedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4Dmedical is operating at the current time. Most of 4Dmedical's value examination focuses on studying past and present price action to predict the probability of 4Dmedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4Dmedical's price. Additionally, you may evaluate how the addition of 4Dmedical to your portfolios can decrease your overall portfolio volatility.